ASSESSMENT OF EFFICACY AND ADVERSE EFFECTS OF TRAZODONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Ali Gul Tunio, Moosa Khan, Dial Das, Ghulam Sarwar

Abstract


Background: Major depressive disorder is a serious and disabling illness in the world and is
common chronic and recurrent disorder. It is the fourth most important cause of worldwide loss in
disability. Methods: This was prospective and open-label study, study conducted in JPMC,
Karachi, to evaluate the efficacy and adverse effects in major depressive disorder individuals. A
total of 40 patients irrespective of the gender, aged 18 years up to 65 years were enrolled from
OPD of Psychiatry Department. Follow-up visits were carried out fortnightly after making
evaluation of symptoms at baseline visit (day 0), follow-up continued till 90 days when the results
were compiled. Results: Statistically significant (p<0.05) results were observed in all the
parameters at the end of study, i.e., day 90. Conclusion: Among all the symptoms of major
depressive disorder, trazodone proved to be more effective in controlling insomnia.
Keywords: Trazodone, major depressive disorder, side effects, anxiolytics

Full Text:

PDF

References


Kasper S, Oliveri L, Di Loreto G, Dionisio P. A comparative,

randomized, double blind study of trazodone prolonged

release and paraoxetine in the treatment of patients with major

depressive disorder. Curr Med Res Opin 2005;21(8):1139–

Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk

WJG, Yuyser J, et al. Triiodothyronine addition to paroxetine

in the treatment of major depressive disorder. J Clin

Endocrinol Metab 2004;89:6271–6.

Fava M, Kendler KS. Major depressive disorder. Neuron

;28:335–41.

Hsu GLK, Wan YM, Adler D, Rand W, Choi E, Tsang BYP.

Detection of major depressive disorder in Chinese Americans

in primary care. Hong Kong J Psychiatry 2005;15:71–6.

Newberg AB, Amsterdam JD, Wintering N, Ploessl K,

Swanson RL, Shults J et al. 123I-ADAM binding to serotonin

transporters in patients with major depression and healthy

controls. A preliminary study. J Nucl Med 2005;46:973–7.

Mann JJ. The medical management of depression. N Eng J

Med 2005;353:1819–34.

De Weid D, Sigling HO. Neuropeptides involved in the

pathophysiology of Schizophrenia and major depression.

Neurotoxicity Res 2002;4:453–68.

Robinson DS. Increased brain MAO-A levels in major

depressive disorder. Primary Psychiatry 2007;32–4.

Marazziti D, Consoli G, Golia F et al. Trazodone effects on

H]-paroxetine and α2-adrenoreceptors in platelets of

patients with major depression. Neuropsychiatric Dis

Arealment 2010;6:255–9.

Finkel R, Clark MA, Cubeddu LX, Harvey RA, Champe PC.

Nefazodone and Trazodone, antidepressant. In: Lippincott’s

Review Pharmacology, 4th Edition. 2009;p.141–58.

Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Bulle C,

Bouchard S, et al. Extented release trazodone in major

depressive disorder. A randomized double blind, plecbo

controlled study. Psychiatry 2009;6(5):20–33.

Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C. The

effects of trazodone on sleep in patients treated with stimulant

antidepressants. Sleep Med. 2004;5(1):15–20.

de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal

overdose with trazodone: case report and literature review.

Acta Clin Belg 2001;56(4):258–61.c


Refbacks

  • There are currently no refbacks.


Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]